Monitoring parameters include blood pressure, heart rate, mood (when treating depressive symptoms), weight, dietary considerations, and suicidal ideation (particularly when initiating therapy or implementing dose increases.) Prescribers or their nursing staff can also evaluate therapeutic effectiveness and assess for any possible adverse reactions; this should occurÂ when initiating treatment and again later with long-term therapy.

There is conflicting evidence regarding the effect of MAO inhibitors on glucose metabolism or whether they can potentiate hypoglycemic therapeutic agents. Therefore, it is prudent to closely monitor blood glucose levels in patients with diabetes who take phenelzine.